Robert Lisicki
Vorstandsvorsitzender bei ZURA BIO LIMITED
Vermögen: - $ am 31.05.2024
Profil
Mr. Robert Lisicki is a Chief Executive Officer & Director at Zura Bio Ltd.
He is on the Board of Directors at Zura Bio Ltd., Adiso Therapeutics, Inc. and Cadrenal Therapeutics, Inc. Mr. Lisicki was previously employed as a Chief Executive Officer & Director by InCarda Therapeutics, Inc., a Chief Commercial Officer & Executive VP by Arena Pharmaceuticals, Inc., a Chief Customer Officer, SVP-Sales & Marketing by Daiichi Sankyo, Inc., a Vice President & General Manager by Amgen, Inc., and a General Manager & Vice President-Cardio Metabolic by Regeneron Pharmaceuticals, Inc. He received his undergraduate degree from State University of New York at Albany.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 06.06.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Robert Lisicki
| Unternehmen | Position | Beginn |
|---|---|---|
| CADRENAL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 23.07.2023 |
| ZURA BIO LIMITED | Vorstandsvorsitzender | 08.04.2024 |
Adiso Therapeutics, Inc.
 Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Direktor/Vorstandsmitglied | 12.10.2023 |
Ehemalige bekannte Positionen von Robert Lisicki
| Unternehmen | Position | Ende |
|---|---|---|
InCarda Therapeutics, Inc.
 InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Vorstandsvorsitzender | 01.03.2023 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01.03.2022 |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Vertrieb & Marketing | 01.04.2018 |
| AMGEN INC. | Corporate Officer/Principal | - |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Robert Lisicki
| State University of New York at Albany | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| ZURA BIO LIMITED | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Health Technology |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Health Technology |
| Cadrenal Therapeutics, Inc. |
